Sobi to present new data across its immunology portfolio at the ACR Convergence 2024
07 nov. 2024 06h59 HE
|
Sobi, Inc.
WALTHAM, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi®), today announced the presentation of four abstracts that...
Sobi to present new myelofibrosis data at the ASCO 2024 Annual Meeting
24 mai 2024 16h15 HE
|
Sobi, Inc.
Sobi will present three abstracts that highlights data from its myelofibrosis treatment option at ASCO.
Sobi Receives US FDA Fast Track Designation for Emapalumab-lzsg being investigated in Macrophage Activation Syndrome
24 mai 2024 15h16 HE
|
Sobi, Inc.
FDA has granted Fast Track designation to emapalumab-lzsg for the potential first therapeutic option in patients with MAS
Santé Canada approuve DOPTELET (avatrombopag) pour deux indications en thrombocytopénie
08 nov. 2023 14h02 HE
|
Sobi, Inc.
WALTHAM, Mass., 08 nov. 2023 (GLOBE NEWSWIRE) -- Sobi Amérique du Nord, la filiale nord-américaine de Swedish Orphan Biovitrum AB (SobiMD), a annoncé aujourd’hui l’approbation par Santé Canada de...
Health Canada Approves DOPTELET (avatrombopag) for Two Indications in Thrombocytopenia
06 nov. 2023 13h07 HE
|
Sobi, Inc.
Health Canada Approves DOPTELET (avatrombopag) for Two Indications in Thrombocytopenia
Annals of Rheumatic Diseases Publishes Results from Phase 2 Study of emapalumab in Patients with Secondary HLH/Macrophage Activation Syndrome
04 avr. 2023 07h00 HE
|
Sobi, Inc.
WALTHAM, Mass., April 04, 2023 (GLOBE NEWSWIRE) -- Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi®) (STO:SOBI), today announced that the Annals of Rheumatic...